GDF-15 was also increased in plasma from the FD patients of our cohort compared to healthy subjects, and showed the same trend as ADAMTS-13, decreasing over time in patients treated with ERT, although these results need to be confirmed in wider cohorts. This evidence concerns the gene ADAMTS13 and Fabry disease.